# Alveolar Echinococcosis: Parasite Viability and Innovative Markers for the Follow-up of Patients Treated With Albendazole

> **NCT02876146** · NA · COMPLETED · sponsor: **Centre Hospitalier Universitaire de Besancon** · enrollment: 50 (actual)

## Conditions studied

- Alveolar Echinococcosis

## Interventions

- **DRUG:** Benzimidazole

## Key facts

- **NCT ID:** NCT02876146
- **Lead sponsor:** Centre Hospitalier Universitaire de Besancon
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2021-08
- **Final completion:** 2021-08
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2021-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02876146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02876146, "Alveolar Echinococcosis: Parasite Viability and Innovative Markers for the Follow-up of Patients Treated With Albendazole". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02876146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*